All
  • All
  • Insight
  • Research Services
  • Preclinical CRO
  • Animal Resource Bank
CN
中文 English
Best-selling laboratory mouse strains

Related Resources

Resource Center

Tau P301S mice

Jiangsu Aniphe BioLab has established a high‑standard laboratory animal breeding platform and maintains an ample supply of Tau P301S transgenic mice, with models available at all ages. Leveraging a mature and stable strain‑maintenance system, the company efficiently fulfills customers’ experimental needs, significantly accelerating research on tau‑related neurodegenerative diseases and addressing the longstanding challenge of lengthy breeding cycles in Alzheimer’s disease models.

Strain Introduction

Tau P301S transgenic mice are among the most widely used models for studying tauopathies in frontotemporal dementia and Alzheimer’s disease. This strain carries the P301S missense mutation, which is associated with familial frontotemporal dementia (FTDP‑17), in the human tau protein (1N4R isoform). Expression is driven by the mouse thymus-specific promoter (Thy1) and is predominantly high in the cerebral cortex, hippocampus, and other forebrain regions.

Beginning at 5–6 months of age, mice exhibit marked tau hyperphosphorylation, insoluble aggregation, and neurofibrillary tangles. By 9–12 months, they display widespread neuronal loss, microglial activation, astrocytic gliosis, and brain atrophy, accompanied by progressive motor dysfunction. This model is suitable for studying tauopathies, neuroinflammation, synaptic damage, and preclinical drug efficacy evaluation.

Product Advantages

Tau pathology forms rapidly and becomes stable.

Expression of the P301S mutant human tau leads to abundant phosphorylated tau aggregates and neurofibrillary tangles as early as 4–6 months of age, with a faster disease‑onset rate than most single‑tau models.

It also exhibits significant neurodegenerative damage.

Beyond mere tau deposition, the accompanying loss of hippocampal and cortical neurons, brain atrophy, and synaptic damage can recapitulate the late‑stage neurodegenerative changes seen in frontotemporal dementia and advanced Alzheimer’s disease.

Accompanied by marked neuroinflammation

In the early stages of the disease, microglia can be activated and astrocytes undergo proliferation, making this model well-suited for screening drugs that modulate neuroinflammation and confer neuroprotection.

The behavioral phenotype is clear.

It is characterized by progressive decline in cognitive and motor functions. Using assays such as the Y-maze and the water maze, the effects of tau‑targeting interventions can be quantitatively assessed, with a well-defined window for evaluating drug efficacy.

Homozygous individuals exhibit a uniform phenotype.

Homozygous mice exhibit high disease‑onset consistency and minimal inter‑individual variability, enabling mechanistic studies and candidate drug screening within a relatively short time frame.

Data parameters

Strain Name Tau P301S transgenic mice
Targeted gene Human MAPT (microtubule-associated protein tau)
Mutant site P301s (c.901C>T, resulting in a proline-to-serine substitution at position 301)
Types of gene editing Random insertion of transgenes (heterozygous maintenance)
Genetic background C57BL/6J
Microbial Grade SPF grade
Available by week of age 3 weeks of age and older

Validate data

Results of the Study on Tau-Related Pathology and Neurodegenerative Changes in PS19 Mice

In PS19 transgenic mice, phosphorylated tau pathology progresses in an age‑dependent manner: at 3 months of age, hippocampal neurons exhibit only weak T14 staining and are PHF1‑negative; by 6 months, tau staining intensifies and PHF1‑positive signals emerge; by 8 months, the number of PHF1‑positive neurons further increases. At 3 months, NFL‑positive labeling is observed in hippocampal mossy fibers of PS19 mice, but this staining is markedly absent by 6 months, suggesting axonal degeneration. Hematoxylin–eosin staining reveals significant brain atrophy and neuronal loss in 12‑month‑old PS19 mice, whereas wild‑type and non‑transgenic mice of the same age show no such pronounced pathological changes. In the spinal cord, tau‑positive spherical structures can be detected as early as 3 months of age. These findings indicate that, in PS19 mice, tau pathology, axonal injury, and alterations in brain architecture progressively worsen with age, recapitulating the age‑related progression of tau‑mediated neurodegeneration.

 

 

In vivo MRI imaging detection

In vivo cranial MRI revealed that, compared with age-matched non-transgenic (nTg) mice, 9-month-old PS19 mice exhibited marked atrophy of the hippocampus and entorhinal cortex, accompanied by ventricular enlargement. Quantitative analysis of brain tissue volume showed that, at 6 months of age, cortical and hippocampal volumes in PS19 mice did not differ significantly from those of the control group; however, starting at 9 months, hippocampal volume declined significantly first, with a reduction approaching 50% by 12 months; cortical volume, by contrast, did not show a noticeable decrease until 12 months of age. These findings suggest that the hippocampus is the primary brain region affected by neuronal loss in PS19 mice, and that brain atrophy progresses in an age‑dependent manner.

 

 

Immunohistochemical test results

Immunohistochemical analysis revealed age‑dependent astroglial proliferation and microglial activation in the central nervous system of PS19 mice. By 3 months of age, GFAP‑positive reactive astrocytes were already evident in the hippocampus, amygdala, cortex, and spinal cord of PS19 mice; by 6 months, the degree of astroglial activation in these same brain regions was significantly lower in WT16 mice. In 4‑month‑old PS19 mice, activated microglia labeled with HLA‑DR and CD11b were observed, accompanied by upregulated expression of IL‑1β and COX‑2, with IL‑1β‑positive signals predominantly localized to neurons in the CA3 region of the hippocampus; by contrast, age‑matched non‑transgenic nTg mice exhibited virtually no detectable expression of these inflammation‑related proteins. Quantitative autoradiographic measurements confirmed that, compared with nTg mice, microglial activation in the hippocampus and entorhinal cortex of PS19 mice began to increase at 3 months of age and continued to intensify with advancing age. These findings suggest that tau pathology can induce glial activation and central inflammatory responses at an early stage, with these processes progressively worsening as the disease progresses.

 

 

Transmission electron microscopy and immunoelectron microscopy analysis

Transmission electron microscopy and immunoelectron microscopy revealed that WT16 mice neurons exhibit abundant mitochondria and well‑preserved endoplasmic reticulum in the cytoplasm, whereas PS19 mice neurons show a reduction in both mitochondrial and endoplasmic reticulum numbers, with some mitochondria displaying swelling. A large number of filamentous structures, 12–20 nm in diameter, are observed in the cytoplasm of PS19 neurons and can be specifically labeled by the tau antibody 17026; immunoelectron microscopy further confirms that these tau filaments accumulate simultaneously in both presynaptic and postsynaptic regions. Moreover, PS19 mice display marked axonal degenerative changes, with some neurons undergoing degeneration even before filamentous aggregates have formed. These ultrastructural findings indicate that tau filaments can accumulate at synaptic sites, accompanied by organelle damage, thereby driving neuronal and axonal degeneration.

 

Application areas

● Research on the pathogenic mechanisms of tau protein: abnormal phosphorylation, aggregation, conformational propagation, prion-like spreading, and the interaction between tau and Aβ.
● Exploration of neuroinflammation: the roles of Trem2, the NLRP3 inflammasome, microglia, and astrocytes in tau pathology.
● Drug efficacy evaluation: tau oligomerization inhibitors, kinase inhibitors, phosphatase activators, anti-tau immunotherapies (active/passive vaccines), neuroprotective small molecules, and others.
● Biomarker discovery: Patterns of change in phosphorylated tau (e.g., p-tau181, p-tau217) and neurofilament light chain (NfL) in cerebrospinal fluid and plasma.
● In vivo functional imaging studies: validation of the specificity of tau-PET tracers, such as [18F]PM-PBB3 and [18F]MK-6240.
● Gene–environment interaction studies: the accelerating effects of chronic stress, sleep deprivation, traumatic brain injury, and other factors on tau pathology.

Breeding Techniques and Precautions

Strictly control inbreeding systems to mitigate genetic divergence.

Caging and Environmental Enrichment

Provide items such as tunnels, nesting materials, and paper rolls. Due to potential locomotor impairments in the later stages, food and water should be placed on the floor or slightly elevated to facilitate access. Starting from the pre‑symptomatic phase, change the bedding 1–2 times per week, keeping it dry and clean to reduce the risk of infection.

Strictly control environmental stimuli to reduce experimental stress.

Nutrition and Feeding

After reaching 6 months of age, the diet can be gradually transitioned to an easily chewable, jelly‑like water‑based formulation or soaked feed to prevent dehydration and wasting. Monitor body weight; if weight loss exceeds 15% or severe paralysis (inability to feed independently) develops, a humane endpoint should be established.

Standardize breeding management to improve the survival rate of pups.

Precise control of phenotypic assessment

Because mouse age is the strongest predictor of disease severity, birth dates must be recorded precisely, and mice should be compared within the same age group and of the same sex. The timing of cage opening and closing should be kept as consistent as possible. When conducting behavioral experiments, allow at least 30 minutes for acclimatization to the testing room, standardize lighting, odor sources, and background noise, and minimize circadian rhythm–related confounding factors.

 

Monitor age-related spontaneous lesions and eliminate experimental confounding.

Health Monitoring

This strain must not be co-housed with other immunodeficient or diseased strains on the same cage rack, and strict adherence to SPF‑grade handling procedures is required. Older male mice may occasionally engage in fighting; aggressive individuals should be housed individually or paired with a female conspecific.

 

Literature support

References: Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model.

Frequently Asked Questions

Image Name

Q1: How does the Tau P301S mouse differ from other tau models, such as Tg4510?

Image Name

A: The P301S (PS19) driver is Thy1, with tau expression more concentrated in the forebrain. This model exhibits a milder onset but rapid progression, and its motor phenotype progresses slightly more slowly than that of Tg4510. Tg4510 is driven by CaMKIIα-tTA, allowing for reversible expression; however, it suffers from transgene‑induced disruption of the Fgf14 gene. Consequently, P301S offers greater advantages for studying tau aggregation and propagation in the absence of such interference.

Image Name

Q2: Why is it recommended to use a wild-type from the same litter as the control?

Image Name

A: Breeding hemizygous transgenic mice yields both positive and wild-type littermates that share the same genetic background and maternal environment, thereby minimizing batch effects, cage‑site effects, and microecological differences, and enhancing the statistical power of experiments.

Image Name

Q3: Can this strain be used in tau propagation/inoculation experiments?

Image Name

A: Yes. Injection of human brain homogenates from Alzheimer’s disease, chronic traumatic encephalopathy, or progressive supranuclear palsy, or of recombinant tau fibrils, into the hippocampus or striatum of P301S mice induces accelerated propagation of tau pathology both at the injection site and in distal connected regions, making this a classic model for studying prion-like transmission and strain-specific properties of tau.

Image Name

Q4: How can phenotypic variability among mice be controlled?

Image Name

A: For each experimental cohort, use individuals of the same sex and born around the same time whenever possible, and prior to the start of the experiment, screen out and exclude animals with clearly impaired motor function based on baseline behavioral assessments. The sample size should generally be ≥12–15 animals per group (accounting for a post‑hoc coefficient of variation in pathology of approximately 20–30%). The experimental report must specify the level of transgene expression (if required, brain‑derived human tau levels may be quantified by ELISA or Western blotting) as a covariate for post‑hoc analyses.

More models